Welcome to our dedicated page for Orthofix Medical news (Ticker: OFIX), a resource for investors and traders seeking the latest updates and insights on Orthofix Medical stock.
Orthofix Medical Inc. (NASDAQ: OFIX) is a leading medical device company providing orthopedic and spine solutions to healthcare providers worldwide. Founded in 1980 by orthopedic researcher Giovanni De Bastiani in Verona, Italy, the company has expanded to over 900 employees and operates in the U.S., Italy, Germany, France, the UK, Brazil, Australia, and Puerto Rico. Orthofix's products serve patients in more than 70 countries, focusing on enhancing patient quality of life through innovative medical solutions.
The company is structured into four strategic business units:
- BioStim: Offering bone growth stimulators using pulsed electromagnetic field technology.
- Biologics: Providing regenerative tissue products and biological solutions for bone and soft tissue repair.
- Extremity Fixation: Specializing in devices for fracture repair, deformity correction, and bone reconstruction.
- Spine Fixation: Delivering comprehensive solutions for spinal implants and bone healing therapies.
Orthofix is committed to clinical research and innovation, continuously introducing new products to meet the evolving needs of the medical community. The company maintains strong partnerships with esteemed institutions like the Texas Scottish Rite Hospital for Children and the Musculoskeletal Transplant Foundation, reflecting its dedication to advancing orthopedic and spine care.
The majority of Orthofix's sales come from its global spine segment, primarily in the United States. The company's products are distributed through sales representatives, distributors, and subsidiaries across North America, Europe, and other international markets. Orthofix's solutions cater to hospitals, physicians, healthcare providers, and patients, aiming to improve treatment outcomes and patient well-being.
Latest News: Stay updated with the latest developments, product launches, and financial reports from Orthofix Medical Inc. to keep track of the company's performance and strategic initiatives.
Orthofix Medical Inc (NASDAQ:OFIX) announced the first patient implant in a pivotal FDA clinical study evaluating the M6-C™ artificial cervical disc for two-level cervical radiculopathy. This study will compare the disc's safety and effectiveness against anterior cervical discectomy and fusion (ACDF). A total of 263 patients will be enrolled, aiming for a primary endpoint of overall success at 24 months. The M6-C disc has been implanted over 55,000 times globally, reinforcing its position as a promising alternative to cervical fusion.
Orthofix Medical Inc. (NASDAQ:OFIX) has announced it will release its second quarter 2021 financial results on Friday, August 6, 2021, before the market opens. The company’s President, Jon Serbousek, and CFO, Doug Rice, will conduct a conference call at 8:30 a.m. ET to discuss the results. Interested parties can access the call by dialing specific numbers or through a webcast available on the company's investor relations website.
Orthofix Medical Inc. (NASDAQ:OFIX) has launched the fiberFUSE™ Strip, a new bone-graft solution for spinal procedures. This innovative product is composed entirely of natural bone and is designed for optimized application in cervical and lumbar surgeries. The fiberFUSE Strip enables cellular ingrowth and new bone formation due to its unique composition. The technology was developed to provide convenience and effectiveness for spine surgeons and their patients. MTF Biologics is the exclusive processor of this product, ensuring high-quality standards through validated aseptic processing.
Orthofix Medical Inc. (NASDAQ:OFIX) announced significant findings from a retrospective study published in The International Journal of Spine Surgery, highlighting a 92.7% fusion rate for patients undergoing three- and four-level lumbar arthrodesis surgery with the SpinalStim device. This data, gathered from 55 patients, reinforces the effectiveness of Pulsed Electromagnetic Field Stimulation (PEMF) therapy even among high-risk patients. The device is FDA-approved for lumbar spinal fusion procedures and is supported by the STIM onTrack mobile app, enhancing patient engagement in recovery.
Orthofix Medical Inc (NASDAQ: OFIX) has launched the FORZA Ti PLIF Spacer System in the U.S., designed for enhancing Posterior Lumbar Interbody Fusion (PLIF) procedures. The device is 3D-printed with optimized porosity and features to support bone ingrowth, critical for surgical success. Key features include a large graft window, titanium endplates with 400 micron pores, and a functional gradient porous structure. The FORZA Ti system is part of Orthofix's growing portfolio of innovative 3D-printed titanium products aimed at improving surgical outcomes.
Orthofix Medical, a global medical device company focused on spine and orthopedics, announced that CEO Jon Serbousek and CFO Doug Rice will participate in a fireside chat at the JMP Securities Life Sciences Conference on June 16, 2021, at 11:00 a.m. ET. The virtual event will include one-on-one meetings and a live audio webcast available on the Company’s website for interested stakeholders.
Orthofix aims to deliver innovative solutions to enhance patient mobility and distributes its products in over 60 countries.
Orthofix Medical Inc. (NASDAQ:OFIX) will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:30 p.m. ET. CEO Jon Serbousek and CFO Doug Rice will lead the discussion. The chat will be followed by one-on-one meetings. A live audio webcast can be accessed on the Company's website.
Orthofix specializes in innovative medical devices and biologics for spine and orthopedics, aiming to enhance patient mobility. Its products are distributed in over 70 countries from its headquarters in Lewisville, Texas.
Orthofix Medical Inc. (NASDAQ: OFIX) continues its sponsorship of Olympic Gold Medalist Laura Wilkinson as she trains for the Tokyo Olympics. Wilkinson, a three-time U.S. Olympic diver, overcame cervical disc degeneration with a successful spine fusion using Orthofix technology. At 39, she returned to diving, aiming to compete in the U.S. Olympic Team Trials from June 6-13, 2021. Orthofix's mission centers on improving patient mobility, and they express pride in supporting Wilkinson's journey while promoting awareness about spine health.
Orthofix Medical Inc. (NASDAQ:OFIX) has launched the OSCAR PRO Ultrasonic Arthroplasty Revision System in the U.S. and Europe. This advanced system aims to improve joint revision surgeries by effectively removing cement from failed implants, addressing challenges faced with traditional methods. As the fourth generation of the OSCAR line, it features an enhanced user interface and new data collection capabilities. The system is significant for the treatment of failed joint replacements, which may require surgical intervention due to cement adhesion.
Orthofix Medical Inc (NASDAQ:OFIX) announced positive preliminary results from the three- and four-year follow-up of its M6-C artificial cervical disc study. The data will be presented at the ISASS annual meeting on May 14. Key findings include a mean Neck Disability Index (NDI) score of 10.9 at three years and 10.3 at four years for M6-C patients, compared to 17.2 and 19.2 for the ACDF group, respectively. The study highlights statistically significant pain score improvements in neck and shoulder/arm pain. The M6-C disc, approved by the FDA in 2019, validates the benefits of cervical disc arthroplasty.
FAQ
What is the current stock price of Orthofix Medical (OFIX)?
What is the market cap of Orthofix Medical (OFIX)?
What does Orthofix Medical Inc. specialize in?
Where is Orthofix Medical Inc. headquartered?
What are the main business units of Orthofix?
How does Orthofix distribute its products?
What partnerships does Orthofix have?
In how many countries are Orthofix products available?
What segment generates the majority of Orthofix's sales?
What are some key products offered by Orthofix?
How many employees does Orthofix have?
When was Orthofix Medical Inc. founded?
